These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 33493384

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Comparison of Immunohistochemistry, Next-generation Sequencing and Fluorescence In Situ Hybridization for Detection of MTAP Loss in Pleural Mesothelioma.
    Febres-Aldana CA, Chang JC, Jungbluth AA, Adusumilli PS, Bodd FM, Frosina D, Geronimo JA, Hernandez E, Irawan H, Offin MD, Rekhtman N, Travis WD, Vanderbilt C, Zauderer MG, Zhang Y, Ladanyi M, Yang SR, Sauter JL.
    Mod Pathol; 2024 Mar; 37(3):100420. PubMed ID: 38185249
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Deletion status of p16 in effusion smear preparation correlates with that of underlying malignant pleural mesothelioma tissue.
    Hida T, Matsumoto S, Hamasaki M, Kawahara K, Tsujimura T, Hiroshima K, Kamei T, Taguchi K, Iwasaki A, Oda Y, Honda H, Nabeshima K.
    Cancer Sci; 2015 Nov; 106(11):1635-41. PubMed ID: 26291840
    [Abstract] [Full Text] [Related]

  • 26. Use of p16 FISH for differential diagnosis of mesothelioma in smear preparations.
    Nabeshima K, Matsumoto S, Hamasaki M, Hida T, Kamei T, Hiroshima K, Tsujimura T, Kawahara K.
    Diagn Cytopathol; 2016 Sep; 44(9):774-80. PubMed ID: 27219841
    [Abstract] [Full Text] [Related]

  • 27. Contribution of BAP1 loss and p16 (CDKN2A) deletion analysis to the definitive diagnosis of mesothelioma in effusion cytology.
    Aydogdu G, Özekinci S.
    Eur Rev Med Pharmacol Sci; 2023 Oct; 27(20):10001-10007. PubMed ID: 37916370
    [Abstract] [Full Text] [Related]

  • 28. Analysis of early pleural fluid samples in patients with mesothelioma: A case series exploration of morphology, BAP1, and CDKN2A status with implications for the concept of mesothelioma in situ in cytology.
    Louw A, van Vliet C, Peverall J, Colkers S, Acott N, Creaney J, Lee YCG, Chai SM.
    Cancer Cytopathol; 2022 May; 130(5):352-362. PubMed ID: 35143119
    [Abstract] [Full Text] [Related]

  • 29. The significance of BAP1 and MTAP/CDKN2A expression in well-differentiated papillary mesothelial tumour: a series of 21 cases and a review of the literature.
    Hassan A, Prabhakaran S, Pulford E, Hocking AJ, Godbolt D, Ziad F, Pandita A, Wessels A, Hussey M, Russell PA, Klebe S.
    Pathology; 2024 Aug; 56(5):662-670. PubMed ID: 38789301
    [Abstract] [Full Text] [Related]

  • 30. 5-hmC loss is another useful tool in addition to BAP1 and MTAP immunostains to distinguish diffuse malignant peritoneal mesothelioma from reactive mesothelial hyperplasia in peritoneal cytology cell-blocks and biopsies.
    Alsugair Z, Kepenekian V, Fenouil T, Glehen O, Villeneuve L, Isaac S, Hommell-Fontaine J, Benzerdjeb N.
    Virchows Arch; 2022 Jul; 481(1):23-29. PubMed ID: 35575935
    [Abstract] [Full Text] [Related]

  • 31. A Combination of MTAP and p16 Immunohistochemistry Can Substitute for CDKN2A Fluorescence In Situ Hybridization in Diagnosis and Prognosis of Pleural Mesotheliomas.
    Brcic L, Le Stang N, Gallob F, Pissaloux D, Sequeiros R, Paindavoine S, Pairon JC, Karanian M, Dacic S, Girard N, Churg A, Tirode F, Galateau-Salle F.
    Arch Pathol Lab Med; 2023 Mar 01; 147(3):313-322. PubMed ID: 35738002
    [Abstract] [Full Text] [Related]

  • 32. Utility of BAP1, p16, and Methylthio-Adenosine Phosphorylase Immunohistochemistry in Cytological and Histological Samples of Pleural Mesotheliomas.
    Amacher V, Bode PK, Moch H, Lenggenhager D, Vrugt B.
    Acta Cytol; 2023 Mar 01; 67(4):444-450. PubMed ID: 36889303
    [Abstract] [Full Text] [Related]

  • 33. BAP1 Immunostain and CDKN2A (p16) FISH Analysis: Clinical Applicability for the Diagnosis of Malignant Mesothelioma in Effusions.
    Walts AE, Hiroshima K, McGregor SM, Wu D, Husain AN, Marchevsky AM.
    Diagn Cytopathol; 2016 Jul 01; 44(7):599-606. PubMed ID: 27121152
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Clinical and molecular validation of BAP1, MTAP, P53, and Merlin immunohistochemistry in diagnosis of pleural mesothelioma.
    Chapel DB, Hornick JL, Barlow J, Bueno R, Sholl LM.
    Mod Pathol; 2022 Oct 01; 35(10):1383-1397. PubMed ID: 35459788
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.